Achieve Life Sciences Nears FDA Decision for Smoking Cessation Drug

TL;DR

**ACHV is a high-risk bet on a single drug's FDA approval, but a positive decision could ignite a massive market opportunity in nicotine cessation.**

AI Summary

Achieve Life Sciences, Inc. (ACHV) is a late-stage clinical specialty pharmaceutical company focused on developing cytisinicline for nicotine dependence. The company reported no revenue for the fiscal year ended December 31, 2025, as it remains in the development phase. A significant development in 2025 was the FDA's acceptance of the New Drug Application (NDA) for cytisinicline for smoking cessation, with a Prescription Drug User Fee Act (PDUFA) targeted action date of June 20, 2026. Additionally, the FDA granted Breakthrough Therapy designation for cytisinicline for nicotine e-cigarette cessation in 2024 and awarded a Commissioner's National Priority Voucher (CNPV) in October 2025 for this indication, which expedites review. The company faces risks including substantial doubt about its ability to continue as a going concern due to the need for additional capital, and potential delays in FDA approval due to a third-party manufacturer's cGMP inspection observations. Achieve has partnered with Adare Pharma Solutions for U.S.-based manufacturing to mitigate supply chain risks, anticipating a commercial launch in the first half of 2027. The strategic outlook centers on securing regulatory approvals and commercializing cytisinicline, which is believed to be differentiated by its efficacy, safety profile, and dosing flexibility.

Why It Matters

Achieve Life Sciences' progress with cytisinicline is critical for investors, as the company has no revenue and its future hinges on regulatory approval and successful commercialization. A positive FDA decision for smoking cessation by June 20, 2026, and the expedited review for e-cigarette cessation, could unlock a significant market addressing the global nicotine dependence epidemic, which causes over eight million deaths worldwide annually. This could position ACHV as a key player against competitors like Pfizer's Chantix (varenicline) and GlaxoSmithKline's Zyban (bupropion), offering a potentially differentiated treatment. Employees and customers stand to benefit from a new, potentially safer and more effective treatment option for nicotine addiction, impacting public health and potentially reducing healthcare utilization.

Risk Assessment

Risk Level: high — Substantial doubt exists regarding Achieve Life Sciences' ability to continue as a going concern, as explicitly stated in the risk factors, indicating a critical need for additional capital. The company's sole product candidate, cytisinicline, faces potential delays in FDA approval beyond the June 20, 2026 PDUFA date due to two observations from a non-Achieve related cGMP inspection at a third-party manufacturer, directly impacting commercialization timelines and financial viability.

Analyst Insight

Investors should closely monitor the FDA's decision on cytisinicline by the June 20, 2026 PDUFA date and the resolution of the third-party manufacturer's cGMP issues. Given the high-risk, high-reward profile, consider a speculative position only if comfortable with significant capital at risk, or wait for clearer regulatory and financial stability signals.

Financial Highlights

debt To Equity

0.0

revenue

$0

operating Margin

N/A

total Assets

$33,500,000

total Debt

$0

net Income

-$48,800,000

eps

-$1.00

gross Margin

N/A

cash Position

$18,600,000

revenue Growth

N/A

Executive Compensation

Key Numbers

• $103,958,994 — Aggregate market value of common stock held by non-affiliates (As of June 30, 2025, indicating market capitalization)
• 53,239,988 — Shares of common stock outstanding (As of March 24, 2026)
• June 20, 2026 — PDUFA targeted action date (For cytisinicline NDA for smoking cessation)
• 2027 — Anticipated commercial launch year (First-half 2027 for cytisinicline)
• 29 million — Adults in the United States who smoke (Represents a significant target market for cytisinicline)
• 17 million — Adults in the United States who utilize e-cigarettes (Represents another significant target market for cytisinicline)
• 8 million — Worldwide deaths annually (Attributable to tobacco use, highlighting the public health crisis cytisinicline aims to address)

Key Players & Entities

• ACHIEVE LIFE SCIENCES, INC. (company) — Registrant
• FDA (regulator) — U.S. Food and Drug Administration
• Sopharma AD (company) — Third-party manufacturer and licensor
• Adare Pharma Solutions (company) — U.S.-based manufacturer partner
• PricewaterhouseCoopers LLP (company) — Auditor
• National Center for Complementary and Integrative Health (company) — Sponsored non-clinical toxicology studies
• National Cancer Institute (company) — Sponsored non-clinical toxicology studies

FAQ

Risk Factors

• Substantial Doubt About Going Concern [high — financial]: The company has incurred significant net losses and negative cash flows from operations since its inception. As of December 31, 2025, ACHV had an accumulated deficit of $249.7 million and expects to continue incurring losses. This raises substantial doubt about its ability to continue as a going concern.
• FDA Approval and Manufacturing Risks [high — regulatory]: The FDA's acceptance of the NDA for cytisinicline is a positive step, but potential delays exist. A third-party manufacturer's facility experienced cGMP inspection observations, which could impact the timely approval and commercialization of cytisinicline. The company is working with Adare Pharma Solutions to mitigate these supply chain risks.
• Market Acceptance and Competition [medium — market]: While cytisinicline targets large markets (29 million smokers and 17 million e-cigarette users in the US), market acceptance is not guaranteed. The company must effectively differentiate its product from existing smoking cessation aids and potential future competitors.
• Reliance on Third-Party Manufacturers [medium — operational]: ACHV relies on third-party manufacturers for the production of cytisinicline. Any disruptions or quality issues at these facilities, as evidenced by the recent cGMP inspection observations, could significantly impact the company's ability to supply its product.
• Need for Future Financing [high — financial]: The company anticipates requiring substantial additional capital to fund its operations, including the potential commercialization of cytisinicline. Failure to secure adequate financing could impede its ability to execute its business plan.

Industry Context

The smoking and nicotine cessation market is a significant public health area with substantial unmet needs, evidenced by millions of users in the US alone. While established therapies exist, there is a continuous demand for more effective and convenient options. Achieve Life Sciences aims to differentiate cytisinicline through its efficacy, safety profile, and dosing flexibility, positioning it as a potentially valuable new entrant.

Regulatory Implications

Achieve Life Sciences is heavily reliant on regulatory approvals from the FDA. The PDUFA date of June 20, 2026, for cytisinicline is a critical inflection point. Potential manufacturing issues, as indicated by cGMP inspection observations, pose a direct risk to the timeline and success of these approvals.

What Investors Should Do

1. Monitor the PDUFA date (June 20, 2026) closely for FDA approval of cytisinicline for smoking cessation. Approval is a key catalyst.
2. Assess the company's ability to secure additional financing, as highlighted by the going concern warning and the need for capital for commercialization.
3. Evaluate the resolution of the cGMP inspection observations with the third-party manufacturer, as this directly impacts supply chain and launch readiness.
4. Track market penetration and competitive response post-launch, should cytisinicline receive approval.

Key Dates

• 2024-01-01: Breakthrough Therapy designation for cytisinicline — Accelerates development and review process for cytisinicline for e-cigarette cessation.
• 2025-10-01: Commissioner's National Priority Voucher (CNPV) awarded — Provides expedited review for cytisinicline for e-cigarette cessation, further enhancing its regulatory pathway.
• 2025-12-31: Fiscal Year End — Reported $0 revenue and a net loss of $48.8 million, highlighting continued development stage and cash burn.
• 2026-03-24: Shares of common stock outstanding reported — Indicates the current equity structure of the company.
• 2026-06-20: PDUFA targeted action date for cytisinicline NDA — Key date for potential FDA approval of cytisinicline for smoking cessation, a critical catalyst for the company.
• 2027-01-01: Anticipated commercial launch of cytisinicline — Marks the potential start of revenue generation if regulatory approvals are secured.

Glossary

PDUFA

Prescription Drug User Fee Act. Sets target dates for FDA action on drug applications. (The PDUFA date of June 20, 2026, is a critical milestone for the potential approval of cytisinicline.)

NDA

New Drug Application. The formal submission to the FDA for approval to market a new drug. (The FDA's acceptance of the NDA for cytisinicline is a significant step towards commercialization.)

Breakthrough Therapy designation

A designation by the FDA to expedite the development and review of drugs for serious or life-threatening conditions. (This designation for cytisinicline for e-cigarette cessation indicates potential for significant improvement over existing therapies.)

cGMP

Current Good Manufacturing Practices. Regulations enforced by the FDA to ensure product quality and safety. (Observations at a third-party manufacturer's cGMP inspection pose a risk to timely product approval and supply.)

CNPV

Commissioner's National Priority Voucher. A voucher awarded by the FDA that can be used to expedite the review of a future marketing application. (The CNPV awarded for cytisinicline for e-cigarette cessation can accelerate its path to market.)

Going Concern

An accounting assumption that a company will continue to operate for the foreseeable future. (The company faces substantial doubt about its ability to continue as a going concern due to its financial condition.)

Year-Over-Year Comparison

The company continues to operate in a pre-revenue stage, with no revenue reported for the fiscal year ended December 31, 2025, similar to the previous year. Net losses remain substantial, with a reported net loss of $48.8 million for 2025, compared to a net loss of $53.1 million for the prior year, indicating a slight improvement in loss containment. A key development is the advancement of cytisinicline through the regulatory process, with the NDA accepted by the FDA and a PDUFA date set for June 20, 2026, a significant positive progression from the prior filing. New risks related to third-party manufacturing cGMP observations have emerged, adding a layer of operational and regulatory uncertainty.

Key Financial Figures

• $0.001 — ch Registered Common Stock, par value $0.001 per share ACHV The Nasdaq Stock Mar

Filing Documents

• achv-20251231.htm (10-K) — 4270KB
• achv-ex10_14.htm (EX-10.14) — 109KB
• achv-ex10_32.htm (EX-10.32) — 70KB
• achv-ex21_1.htm (EX-21.1) — 4KB
• achv-ex23_1.htm (EX-23.1) — 4KB
• achv-ex31_1.htm (EX-31.1) — 12KB
• achv-ex31_2.htm (EX-31.2) — 15KB
• achv-ex32_1.htm (EX-32.1) — 6KB
• achv-ex32_2.htm (EX-32.2) — 7KB
• 0001193125-26-120690.txt ( ) — 16595KB
• achv-20251231.xsd (EX-101.SCH) — 2082KB
• achv-20251231_htm.xml (XML) — 3348KB

BUSINESS

BUSINESS 5 ITEM 1A.

RISK FACTORS

RISK FACTORS 21 ITEM 1B. UNRESOLVED STAFF COMMENTS 54 ITEM 1C. CYBERSECURITY 54 ITEM 2.

PROPERTIES

PROPERTIES 55 ITEM 3.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 55 ITEM 4. MINE SAFETY DISCLOSURE 55 PART II 56 ITEM 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 56 ITEM 6. RESERVED 56 ITEM 7.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 57 ITEM 7A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 66 ITEM 8.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 67 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 98 ITEM 9A.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 98 ITEM 9B. OTHER INFORMATION 98 ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 98 PART III 99 ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 99 ITEM 11.

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 99 ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 99 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 99 ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES 99 PART IV 100 ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES 100 ITEM 16. FORM 10-K SUMMARY 105

SIGNATURES

SIGNATURES 105 P ART I References in this Form 10-K to "Achieve Life Sciences," "Achieve," the "Company," "we," "us" or "our" refer to Achieve Life Sciences, Inc. and its wholly owned subsidiaries. The information in this Annual Report on Form 10-K contains certain forward-looking statements, including statements related to clinical trials, regulatory approvals, markets for our products, new product development, capital requirements and trends in our business that involve risks and uncertainties. Our actual results may differ materially from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed in "Business," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," as well as those discussed elsewhere in this Annual Report on Form 10-K.

Forward-Looking Statements

Forward-Looking Statements This Annual Report on Form 10-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties. We caution readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement. These statements are based on current expectations of future events. Such statements include, but 2 are not limited to, statements about future financial and operating results, plans, objectives, expectations and intentions, costs and expenses, interest rates, outcome of contingencies, financial condition, results of operations, liquidity, business strategies, cost savings, objectives of management and other statements that are not historical facts. You can find many of these statements by looking for words like "believes," "expects," "anticipates," "estimates," "may," "should," "will," "could," "plan," "intend" or similar expressions in this Annual Report on Form 10-K or in documents incorporated by reference into this Annual Report on Form 10-K. We intend that such forward-looking statements be subject to the safe harbors created thereby. Examples of these forward-looking statements include, but are not limited to: anticipated regulatory filings and U.S. Food and Drug Administration, or FDA, responses, recommendations, requirements or additional future clinical trials; our ability to raise additional capital as needed to fund our planned development and commercialization efforts and service our existing debt; the potential benefits and differentiated profile, FDA approval, commercialization and commercial market for cytisinicline; the ability of our third-party manufacturers to receive and maintain FDA approval, and provide sufficient supply of cytisinicline in a timely manner; progress and preliminary and f

View Full Filing

View this 10-K filing on SEC EDGAR